MX2021008941A - Moduladores gpr35. - Google Patents

Moduladores gpr35.

Info

Publication number
MX2021008941A
MX2021008941A MX2021008941A MX2021008941A MX2021008941A MX 2021008941 A MX2021008941 A MX 2021008941A MX 2021008941 A MX2021008941 A MX 2021008941A MX 2021008941 A MX2021008941 A MX 2021008941A MX 2021008941 A MX2021008941 A MX 2021008941A
Authority
MX
Mexico
Prior art keywords
gpr35
modulators
gpr35 modulators
compounds
disorders
Prior art date
Application number
MX2021008941A
Other languages
English (en)
Inventor
Robert Higuchi
Original Assignee
Prometheus Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prometheus Biosciences Inc filed Critical Prometheus Biosciences Inc
Publication of MX2021008941A publication Critical patent/MX2021008941A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds

Abstract

Se describen en la presente, moduladores GPR35 y métodos para usar estos compuestos en el tratamiento de enfermedades, trastornos o afecciones. También se describen en la presente composiciones farmacéuticas que contienen tales compuestos.
MX2021008941A 2019-01-24 2020-01-23 Moduladores gpr35. MX2021008941A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962796459P 2019-01-24 2019-01-24
US201962873703P 2019-07-12 2019-07-12
US201962928223P 2019-10-30 2019-10-30
PCT/US2020/014777 WO2020154492A1 (en) 2019-01-24 2020-01-23 Gpr35 modulators

Publications (1)

Publication Number Publication Date
MX2021008941A true MX2021008941A (es) 2021-10-13

Family

ID=71733100

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021008941A MX2021008941A (es) 2019-01-24 2020-01-23 Moduladores gpr35.

Country Status (13)

Country Link
US (2) US11053251B2 (es)
EP (1) EP3914256A4 (es)
JP (1) JP2022518523A (es)
KR (1) KR20210119485A (es)
CN (1) CN113631168A (es)
AU (1) AU2020210930A1 (es)
BR (1) BR112021014566A2 (es)
CA (1) CA3127786A1 (es)
IL (1) IL285074A (es)
MA (1) MA54825A (es)
MX (1) MX2021008941A (es)
TW (1) TW202043234A (es)
WO (1) WO2020154492A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202043234A (zh) 2019-01-24 2020-12-01 美商普羅米修斯生物科學股份有限公司 Gpr35調節劑
TW202219047A (zh) * 2020-07-23 2022-05-16 美商普羅米修斯生物科學股份有限公司 靶向gpr35之治療劑

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1338235A (en) * 1970-12-15 1973-11-21 May & Baker Ltd Azapurinones
GB1421970A (en) * 1973-06-12 1976-01-21 May & Baker Ltd 8-azapurin-6-one derivatives
US4052390A (en) * 1973-06-12 1977-10-04 May & Baker Limited Azapurinones
GB1561345A (en) 1976-10-22 1980-02-20 May & Baker Ltd 8 - azapuring - 6 - ones
US4923874A (en) * 1988-07-21 1990-05-08 G. D. Searle & Co. Use of 8-azapurin-6-one derivatives for control of hypertension
US5474796A (en) 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface
FR2845993B1 (fr) * 2002-10-16 2005-02-11 Univ Pasteur Composes pharmaceutiques inhibiteurs specifiques de la pde5 du muscle lisse, compositions pharmaceutiques les contenant et utilisations therapeutiques
US20070287630A1 (en) 2006-06-12 2007-12-13 Driwater, Inc. Moisturizing agent with nutrients
AU2012262021B2 (en) * 2011-06-01 2016-07-28 Janus Biotherapeutics, Inc. Novel immune system modulators
ES2943498T3 (es) 2013-08-05 2023-06-13 Twist Bioscience Corp Genotecas sintetizadas de novo
US20150273088A1 (en) * 2014-03-28 2015-10-01 Washington University Zaprinast analogues as glutaminase inhibitors and methods to predict response thereto
WO2016003901A1 (en) 2014-06-29 2016-01-07 Profile Products L.L.C. Bark and wood fiber growing medium
WO2018195328A1 (en) 2017-04-20 2018-10-25 Cedars-Sinai Medical Center Methods of predicting non-response to anti-tnf treatment in subjects with inflammatory bowel disease
WO2019210203A1 (en) 2018-04-27 2019-10-31 Cedars-Sinai Medical Center Compositions and methods of targeting gpr35 for the treatment of inflammatory bowel conditions
TW202043234A (zh) 2019-01-24 2020-12-01 美商普羅米修斯生物科學股份有限公司 Gpr35調節劑
MA54903A (fr) 2019-02-08 2021-12-15 Cedars Sinai Medical Center Méthodes, compositions et kits pour traiter une maladie inflammatoire ciblant il18r1
CA3128942A1 (en) 2019-02-08 2020-08-13 Cedars-Sinai Medical Center Methods, systems, and kits for treating inflammatory disease targeting skap2
EP3969621A4 (en) 2019-05-14 2023-01-25 Prometheus Biosciences, Inc. TL1A PATIENT SELECTION METHODS, SYSTEMS AND DEVICES
WO2021108694A1 (en) 2019-11-27 2021-06-03 Cedars-Sinai Medical Center Predicting extraintestinal manifestations of inflammatory bowel disease
TW202219047A (zh) 2020-07-23 2022-05-16 美商普羅米修斯生物科學股份有限公司 靶向gpr35之治療劑
EP4244251A1 (en) 2020-11-13 2023-09-20 Prometheus Biosciences, Inc. Methods, systems, and kits for treatment of inflammatory diseases targeting tl1a
WO2022140283A1 (en) 2020-12-21 2022-06-30 Cedars-Sinai Medical Center Tl1a therapy compositions and methods of treatment therewith

Also Published As

Publication number Publication date
WO2020154492A1 (en) 2020-07-30
JP2022518523A (ja) 2022-03-15
MA54825A (fr) 2021-12-01
IL285074A (en) 2021-09-30
AU2020210930A1 (en) 2021-09-09
TW202043234A (zh) 2020-12-01
US11053251B2 (en) 2021-07-06
EP3914256A4 (en) 2022-09-28
KR20210119485A (ko) 2021-10-05
US20200239476A1 (en) 2020-07-30
CN113631168A (zh) 2021-11-09
US11773101B2 (en) 2023-10-03
US20210380590A1 (en) 2021-12-09
BR112021014566A2 (pt) 2022-01-04
CA3127786A1 (en) 2020-07-30
EP3914256A1 (en) 2021-12-01

Similar Documents

Publication Publication Date Title
PH12020500066A1 (en) Carboxamides as modulators of sodium channels
PH12019502058A1 (en) Farnesoid x receptor agonists and uses thereof
MX2019000588A (es) Moduladores de la somatostatina y usos de los mismos.
MX2019010949A (es) Moduladores de somatostatina y usos de los mismos.
MX2017015574A (es) Inhibidores de tirosina quinasa de bruton.
PH12018502438A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12021550605A1 (en) Farnesoid x receptor agonists and uses thereof
PH12019500208A1 (en) Spiro-lactam nmda receptor modulators and methods of using same
MX2020007586A (es) Proceso de fabricacion de moduladores de somatostatina.
MX2021011723A (es) Ligandos de pseudocinasa tyk2.
MX2021009555A (es) Ligandos de pseudocinasa tyk2.
PH12020551144A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MX2020013085A (es) Antagonistas del receptor de subtipo 2 de melanocortina (mc2r) y usos de los mismos.
MX2022009762A (es) Moduladores del purinorreceptor 3 p2x (p2x3).
MX2021015500A (es) Pirazolo-pirazinas sustituidas y su uso como moduladores del receptor glun2b.
MX2022001874A (es) Receptores agonistas no peptidicos de somatostatina tipo 5 y usos de los mismos.
CR20220215A (es) Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1
MX2022000712A (es) Moduladores de nlrp3.
MX2022005563A (es) Ligandos de la pseudoquinasa tyk2.
MX2021015506A (es) Amidas de pirazolo-piridina sustituidas y su uso como moduladores del receptor glun2b.
CR20220216A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
MX2021002916A (es) Pirfenidona enriquecida con deuterio y métodos para su uso.
PH12019500949A1 (en) Ror-gamma modulators
MX2021013602A (es) Inhibidores de jak.
MX2023003677A (es) Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.